Rashtriya Newsflash

Myositis Clinical Trial

According to DelveInsight’s latest report, “Myositis Pipeline Insight, 2026,” over 40 leading biopharmaceutical companies and research institutions are actively engaged in developing more than 45 pipeline therapies aimed at addressing the complex and heterogeneous nature of idiopathic inflammatory myopathies (IIMs).

The Myositis therapeutic landscape is entering a transformative phase, driven by scientific innovation, increasing disease awareness, and a rapidly expanding pipeline of targeted therapies.

DelveInsight’s comprehensive report offers a deep dive into the Myositis pipeline, covering drug profiles across clinical and nonclinical stages, therapeutic segmentation by molecule type and route of administration, and detailed insights into inactive and discontinued programs. The study further provides a strategic assessment of clinical trial activity, collaborations, licensing deals, and emerging technological platforms shaping the future of Myositis treatment.

Discover the Future of Myositis Treatment. Gain access to in-depth pipeline insights, emerging therapies, and competitive intelligence: Myositis Pipeline Outlook

Key Takeaways from the Myositis Pipeline Report

• The Myositis pipeline includes over 45 active therapies across multiple clinical stages.
• More than 40 companies are actively engaged in Myositis drug development globally.
• Increasing focus on targeted immunomodulation and cytokine inhibition is reshaping treatment approaches.
• Advanced therapies such as CAR T-cell treatments and gene-based interventions are emerging as promising options.
• Strategic collaborations, mergers, and licensing agreements are accelerating pipeline progress.
• Precision medicine and biomarker-driven approaches are expected to enhance patient outcomes.
• Growing emphasis on addressing unmet needs in rare and refractory Myositis subtypes.
• In March 2026, Abcuro, Inc., a clinical stage biotechnology company, presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026 in Lisbon, Portugal from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with inclusion body myositis (IBM). IBM is a rare, debilitating and relentlessly progressive chronic autoimmune disease that currently has no approved treatment options.
• In February 2026, Abcuro, Inc., announced topline results from the Phase 2/3 MUSCLE clinical study of ulviprubart (ABC008), an investigational monoclonal antibody in development for the treatment of patients with inclusion body myositis (IBM), a rare, debilitating and relentlessly progressive chronic autoimmune disease that currently has no approved treatment options. The MUSCLE study did not meet its primary endpoint, assessed by the IBM Functional Rating Scale (IBMFRS) total score at Week 76 compared to placebo, or key secondary endpoints. While the results did not achieve statistical significance, a pre-specified subgroup analysis in patients with mild to moderate disease at baseline showed trends in improvement in the IBMFRS total score and key secondary endpoints, suggesting the potential of ulviprubart’s disease modifying activity in such patients. Importantly, ulviprubart showed a favorable safety and tolerability profile compared to placebo, and no safety signals were identified at the doses studied.
• In November 2025, Cartesian Therapeuticsannounced its planned expansion into myositis given the strong mechanistic alignment with existing clinical data in MG and systemic lupus erythematosus (SLE). Cartesian announced the U.S. Food and Drug Administration (FDA) accepted the investigational new drug (IND) application for its planned Phase 2 trial in myositis. The Company plans to initiate this Phase 2 seamless adaptive clinical trial, which offers a potential opportunity for a single pivotal trial in the first half of 2026. The randomized, double-blind, placebo-controlled Phase 2 trial in myositis (TRITON) is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in up to 50 participants with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome. The primary endpoint is expected to assess safety and efficacy of Descartes-08 compared to placebo added to standard of care in participants with myositis at Week 24. An interim analysis is expected after ten participants are enrolled and reach the primary endpoint, at which point sample size assumptions will be revised to what is necessary to support a potential seamless pivotal trial, pending FDA review based on the preliminary efficacy data available at such time.
• In March 2025, Abcuro, Inc., a clinical-stage biotech firm focused on treating autoimmune diseases and cancer by precisely targeting cytotoxic T cells, announced it will present safety, pharmacokinetic, and pharmacodynamic findings from its Phase 1 clinical trial of ulviprubart (ABC008) for inclusion body myositis (IBM) at the upcoming American Academy of Neurology (AAN) Annual Meeting.
• In February 2025, Abcuro secured $200 million in Series C funding to advance the development of its first-in-class therapy for inclusion body myositis. The funding will support the completion of the registrational Phase 2/3 MUSCLE trial evaluating ulviprubart, as well as the preparation for its Biologics License Application (BLA) submission and eventual commercial launch.

Understanding Myositis: A Complex Autoimmune Disorder

Myositis, commonly referred to as idiopathic inflammatory myopathies (IIMs), represents a group of rare autoimmune diseases characterized by chronic inflammation and progressive skeletal muscle weakness. These conditions often extend beyond muscle involvement, affecting vital organs such as the lungs, heart, and gastrointestinal system, thereby significantly increasing morbidity and healthcare burden.

Major subtypes of Myositis include dermatomyositis (DM), polymyositis (PM), juvenile dermatomyositis (JDM), inclusion body myositis (IBM), immune-mediated necrotizing myopathy (IMNM), and antisynthetase syndrome. Each subtype presents unique clinical, pathological, and immunological characteristics, contributing to diagnostic complexity and therapeutic challenges.

Patients frequently exhibit symptoms such as symmetric proximal muscle weakness, fatigue, dysphagia, and systemic manifestations including interstitial lung disease, fever, and Raynaud’s phenomenon. Dermatomyositis is distinguished by characteristic skin rashes, while polymyositis primarily involves muscle inflammation. Inclusion body myositis and necrotizing myopathy follow distinct progression patterns, often leading to long-term disability.

The pathophysiology of Myositis involves a combination of innate and adaptive immune responses. Muscle injury triggers the release of damage-associated molecular patterns (DAMPs), activating Toll-like receptors and promoting inflammatory cytokine production. CD8+ T-cell-mediated cytotoxicity, autoantibody-driven complement activation, mitochondrial dysfunction, and oxidative stress collectively contribute to muscle fiber damage and chronic inflammation.

Diagnosis requires a comprehensive approach that integrates clinical evaluation, laboratory testing, imaging techniques such as MRI, electromyography (EMG), and muscle biopsy. The 2017 EULAR/ACR classification criteria play a critical role in differentiating Myositis subtypes and guiding treatment strategies.

Current treatment approaches rely heavily on high-dose glucocorticoids, followed by immunosuppressive agents such as methotrexate, azathioprine, and mycophenolate mofetil. While these therapies provide symptomatic relief, limitations such as relapse risk, long-term side effects, and variable patient response underscore the urgent need for more targeted and durable treatment options.

Evolving Myositis Pipeline Landscape: Innovation at the Forefront

The Myositis pipeline is witnessing unprecedented growth, fueled by advancements in immunology, molecular biology, and precision medicine. Researchers are increasingly focusing on targeted mechanisms that address the underlying immune dysregulation driving disease progression.

Emerging therapies aim to modulate cytokine signaling pathways, reduce autoantibody production, and restore immune homeostasis. Novel approaches such as CAR T-cell therapy, gene editing technologies, and TYK2 inhibition are gaining traction, reflecting a shift toward personalized and mechanism-based treatment strategies.

The report highlights that more than 45 pipeline candidates are currently under development across various stages, from early discovery to late-stage clinical trials. This diverse portfolio includes monoclonal antibodies, small molecules, recombinant proteins, and advanced cell therapies, demonstrating the breadth of innovation in this space.

Request Sample Insights and Competitive Intelligence. Explore detailed clinical data, drug mechanisms, and strategic developments: Myositis Competitive Landscape

Myositis Emerging Drugs Profile

PF-06823859: Pfizer

PF-06823859 is a humanized monoclonal antibody targeting interferon-beta, designed to inhibit key inflammatory signaling pathways involved in Myositis. By reducing immune-mediated inflammation in muscle and skin tissues, the therapy aims to improve muscle strength and decrease disease activity. Currently in Phase III clinical trials, PF-06823859 represents one of the most advanced candidates in the Myositis pipeline.

GLPG3667: Galapagos NV

GLPG3667 is an oral TYK2 inhibitor that selectively modulates cytokine signaling pathways associated with autoimmune diseases. By blocking signaling from type I interferons and interleukins such as IL-12 and IL-23, the therapy aims to reduce inflammation and improve clinical outcomes in dermatomyositis and polymyositis. It is currently in Phase II development.

FT819: Fate Therapeutics

FT819 is an innovative allogeneic CAR T-cell therapy targeting CD19-positive B cells. Developed using induced pluripotent stem cell (iPSC) technology, this off-the-shelf therapy aims to reduce autoantibody production and modulate aberrant immune responses. Currently in Phase I trials, FT819 represents a cutting-edge approach to treating autoimmune conditions such as Myositis.

These therapies exemplify the shift toward targeted, mechanism-driven treatment strategies that address the root causes of Myositis rather than merely managing symptoms.

Access Full Drug Profiles and Clinical Updates. Stay informed on emerging therapies and pipeline progress: Myositis Drugs and Therapies

Myositis Pipeline Segmentation and Therapeutic Assessment

The Myositis clinical trial report provides a comprehensive segmentation of pipeline drugs based on clinical stage, route of administration, and molecule type, offering valuable insights into therapeutic trends and innovation patterns.

Myositis Clinical Development Stages

• Phase III (Late-stage)
• Phase II (Mid-stage)
• Phase I (Early-stage)
• Preclinical and Discovery
• Inactive and Discontinued Programs

Myositis Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myositis Molecule Types

• Monoclonal antibodies
• Small molecules
• Recombinant fusion proteins
• Peptides
• Gene therapies
• Polymer-based therapies

Myositis Product Types

• Monotherapy
• Combination therapy
• Mono/Combination approaches

Myositis Clinical Trial and Development Activities

The Myositis pipeline is characterized by a robust increase in global clinical trial activity. Companies are actively exploring partnerships, licensing agreements, and acquisitions to enhance their R&D capabilities and accelerate product development timelines.

Key Myositis players such as Pfizer, Galapagos NV, and Fate Therapeutics are leading clinical innovation, while emerging biotech firms are contributing novel therapeutic platforms such as CAR T-cell therapies and gene editing technologies.

Collaborative efforts between industry and academia are also playing a crucial role in advancing research, improving clinical trial design, and identifying new therapeutic targets.

Download sample report to get competitive edge on your competitors: Myositis Clinical Trial and FDA Approvals

Myositis Market Drivers, Challenges, and Future Outlook

Key Myositis Market Growth Drivers

• Rising prevalence and improved diagnosis of rare autoimmune diseases
• Advancements in immunology and molecular biology
• Increasing investment in rare disease research
• Growing adoption of precision medicine approaches
• Expanding pipeline of targeted therapies

Myositis Market Challenges

• Disease heterogeneity and complex pathophysiology
• Lack of standardized biomarkers for diagnosis and monitoring
• High cost of advanced therapies
• Limited patient populations for clinical trials

Despite these challenges, the Myositis market is poised for significant growth. The integration of artificial intelligence, biomarker discovery, and advanced therapeutic platforms is expected to revolutionize treatment paradigms and improve patient outcomes.

Scope of the Myositis Pipeline Report

• Coverage: Global
• Key Myositis Companies: Pfizer, Galapagos NV, Fate Therapeutics, Bristol-Myers Squibb, Gilead Sciences, CRISPR Therapeutics, and others
• Key Myositis Therapies: PF-06823859, GLPG3667, FT819, ALLO-329, ADI-001, CNTY-101, and more
• Myositis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myositis Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Download free sample report now: Myositis Companies and Medication

Table of Contents

1. Introduction
2. Executive Summary
3. Myositis Overview
4. Myositis Pipeline Therapeutics
5. Myositis Therapeutic Assessment
6. Analytical Perspective
7. Late-Stage Myositis Products
8. Mid-Stage Myositis Products
9. Early-Stage Myositis Products
10. Inactive Myositis Products
11. Key Myositis Companies
12. Key Myositis Products
13. Myositis Unmet Needs
14. Myositis Market Drivers and Barriers
15. Future Perspectives

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting